Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):174-187. doi: 10.1016/j.ijrobp.2017.09.033. Epub 2017 Sep 22.

Abstract

Purpose: We previously reported that sphere-forming non-small cell lung cancer (NSCLC) tumor-initiating cells (TICs) have an altered activation of DNA damage response- and repair proteins and are refractory to DNA-damaging treatments. We analyzed whether chromatin organization plays a role in the observed refractoriness.

Methods and materials: Bulk cells and TICs from the NSCLC H23 and H1299 cell lines were examined using cell viability, clonogenic survival, Western blot, short interfering RNA analysis, and micronucleus assay.

Results: NSCLC TICs displayed elevated heterochromatin markers trimethylated lysine 9 of histone H3 and heterochromatin protein 1γ relative to bulk cells and reduced cell viability upon histone deacetylase inhibition (HDACi). Vorinostat and trichostatin A increased the euchromatin markers acetylated lysine 9/14 of histone H3 and lysine 8 of histone H4, and HDACi pretreatment increased the phosphorylation of the DNA damage response proteins ataxia telangiectasia mutated and DNA-dependent protein kinase, catalytic subunit, upon irradiation in TICs. HDACi sensitized TICs to cisplatin and to some extent to ionizing irradiation. The protectiveness of a dense chromatin structure was indicated by an enhanced frequency of micronuclei in TICs following irradiation, after knockdown of heterochromatin protein 1γ.

Conclusions: Although confirmatory studies in additional NSCLC model systems and with respect to analyses of other DNA damage response proteins are needed, our data point toward a heterochromatic structure of NSCLC TICs, such that HDACi can sensitize TICs to DNA damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AC133 Antigen / metabolism
  • Antineoplastic Agents / pharmacology
  • Blotting, Western
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Carcinoma, Non-Small-Cell Lung / therapy
  • Cell Line, Tumor
  • Cell Survival
  • Chromatin / chemistry
  • Chromatin / drug effects*
  • Chromosomal Proteins, Non-Histone / genetics
  • Cisplatin / pharmacology
  • DNA Damage*
  • Heterochromatin / chemistry
  • Heterochromatin / drug effects
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / therapy
  • Micronucleus Tests
  • Nanog Homeobox Protein / metabolism
  • Neoplastic Stem Cells / chemistry
  • Neoplastic Stem Cells / drug effects*
  • Neoplastic Stem Cells / metabolism
  • Octamer Transcription Factor-3 / metabolism
  • Phosphorylation
  • RNA, Small Interfering / analysis
  • SOXB1 Transcription Factors / metabolism

Substances

  • AC133 Antigen
  • Antineoplastic Agents
  • CBX3 protein, human
  • Chromatin
  • Chromosomal Proteins, Non-Histone
  • Heterochromatin
  • Histone Deacetylase Inhibitors
  • NANOG protein, human
  • Nanog Homeobox Protein
  • Octamer Transcription Factor-3
  • POU5F1 protein, human
  • RNA, Small Interfering
  • SOX2 protein, human
  • SOXB1 Transcription Factors
  • Cisplatin